VINCERX PHARMA INC (VINC)

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 41 full-time employees. The company went IPO on 2020-03-10. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.

Company Info

VINCERX PHARMA INC

260 Sheridan Avenue, Suite 400

Palo Alto CALIFORNIA 94306

P: 16508006676

CEO: Ahmed M. Hamdy

Employees: 41

Website: https://vincerx.com/